Mizuho Securities USA LLC has initiated coverage with a ‘Buy’ rating and price target of $28.00 on shares of Zogenix, Inc.’s (NASDAQ: ZGNX) stock after the company hit a new 52-week high on Wednesday. The company’s lead product candidate for the treatment of seizures associated with Dravet syndrome, ZX008, was noted by the analyst as having a strong efficacy. The analyst also cited clinical data that suggests ZX008 shows a superior long-term efficacy profile over its competitors with tolerable side effects. Upcoming catalysts for the company include phase 3 read-outs in the third quarter of 2017, and either the fourth quarter of 2017 or the first quarter of 2018.
For more information, visit www.Zogenix.com
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
More from NetworkNewsBreaks
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.NetworkNewsWire.com